FIELD: medicine.
SUBSTANCE: skeletal muscle ischemia in laboratory animals is corrected by simulating leg muscle ischemia on the second experimental day. That is ensured by the instragastric administration of nicorandyl 1.3 mg/kg in two stages on the first, fourth and seventh experimental day.
EFFECT: effective treatment of the skeletal muscle ischemia by stimulated neovasculogenesis.
Title | Year | Author | Number |
---|---|---|---|
METHOD FOR PHARMACOLOGICAL CORRECTION OF SCELETAL MUSCLE ISCHEMIA WITH MINOXIDIL | 2012 |
|
RU2497200C1 |
METHOD FOR PHARMACOLOGICAL CORRECTION OF SKELETAL MUSCLE ISCHEMIA WITH L-NORVALINE | 2012 |
|
RU2507596C1 |
METHOD OF PHARMACOLOGICAL CORRECTION OF ISCHEMIA OF SKELETAL MUSCLE WITH RESVERATROL | 2012 |
|
RU2518965C1 |
METHOD OF PHARMACOLOGICAL CORRECTION OF SCELETAL MUSCLE ISCHEMIA WITH SILNEDAFIL INCLUDING IN L-NAME INDUCED NITROGEN OXIDE DEFICIENCY | 2012 |
|
RU2497203C2 |
METHOD FOR STIMULATING NEOANGIOGENESIS IN ISCHEMIC SKELETAL MUSCLE | 2014 |
|
RU2547692C1 |
METHOD FOR PHARMACOLOGICAL CORRECTION OF EXPERIMENTAL CRITICAL SKELETAL MUSCLE ISCHEMIA WITH A COMBINATION OF SIMVASTATIN AND MONONUCLEAR FRACTION OF AUTOLOGOUS BONE MARROW | 2020 |
|
RU2735838C1 |
METHOD FOR SKELETAL MUSCLE EXPERIMENTAL ISCHEMIA PHARMACOLOGICAL CORRECTION USING TADALAFIL AND PENTOXIFYLLINE IN COMBINED THERAPY | 2016 |
|
RU2618620C1 |
METHOD FOR SKELETAL MUSCLE EXPERIMENTAL ISCHEMIA PHARMACOLOGICAL CORRECTION USING SILDENAFIL AND PENTOXIFYLLINE IN COMBINED THERAPY | 2016 |
|
RU2618621C1 |
METHOD FOR PREVENTION OF ISCHEMIA OF RETINA EXPERIMENTALLY | 2013 |
|
RU2539630C1 |
METHOD FOR PHARMACOLOGICAL CORRECTION OF EXPERIMENTAL CRITICAL SKELETAL MUSCLE ISCHEMIA WITH SIMVASTATIN | 2020 |
|
RU2726076C1 |
Authors
Dates
2014-02-20—Published
2012-05-23—Filed